Information for "Impact and clinical worth of the changed 2019 China HER2 testing recommendations on the discover result evaluation of obtrusive breast cancers instances along with equivocal HER2 immunostaining by using fluorescence inside situ hybridization"
From EECH Central
Basic information
| Display title | Impact and clinical worth of the changed 2019 China HER2 testing recommendations on the discover result evaluation of obtrusive breast cancers instances along with equivocal HER2 immunostaining by using fluorescence inside situ hybridization |
| Default sort key | Impact and clinical worth of the changed 2019 China HER2 testing recommendations on the discover result evaluation of obtrusive breast cancers instances along with equivocal HER2 immunostaining by using fluorescence inside situ hybridization |
| Page length (in bytes) | 3,400 |
| Page ID | 1311176 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Jackettip9 (Talk | contribs) |
| Date of page creation | 08:45, 28 March 2024 |
| Latest editor | Jackettip9 (Talk | contribs) |
| Date of latest edit | 08:45, 28 March 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 1 |
| Recent number of distinct authors | 1 |
